Compare MP Materials (MP) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MP Materials vs Organon & Co. Common Stock — how do they compare? MP Materials trades at $39.65 (market cap $7.56B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: MP Materials is far larger — about 2.1× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while MP Materials pays none. Which is the better fit depends on your goals — on Pluang, investors hold MP Materials for 14 Days and Organon & Co. Common Stock for 0 Days on average.
| MP | OGN | |
|---|---|---|
Market Cap | $7.56B | $3.62B |
Volume | 5,062,845 | 2,892,999 |
Sector | Basic Materials | Health |
52-Week High | $89.85 | $13.81 |
52-Week Low | $38.10 | $5.70 |
Typical Hold Time | 14 Days | 0 Days |
Enterprise Value | $7.04B | $11.04B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MP Materials (MP) trades at $42.43, down 2.14% today, amid bearish technical signals and mixed fundamentals. The stock shows negative profitability metrics with a -19.85% net income margin and -4.08% ROE, though revenue growth is projected from $224M in 2025 to $305M in 2026. Analyst sentiment remains strongly bullish with 13 buy ratings and a $80.70 consensus price target, representing significant upside potential from current levels despite recent price weakness.
The investment case hinges on MP's strategic position in rare earths production and U.S. government support for domestic supply chains. Key risks include persistent negative cash flow from operations, high valuation multiples (P/S 24.64), and sector volatility. The upcoming Q3 2026 earnings report on November 5 will be critical for validating the company's growth trajectory and path to profitability.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MP Materials
MP Materials mines, refines, and manufactures rare earth materials and magnets in the United States. Its products are used in transportation, energy, robotics, defense, and aerospace applications.
Read more on MP →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
